key: cord-0987443-phmvqhsm authors: Xiong, Xiaoli; Chua, Gilbert T.; Chi, Shuiqing; Wah Kwan, Mike Yat; Sang Wong, Wilfred Hing; Zhou, Aifen; Shek, Chi Chiu; Tung, Keith TS.; Qin, Huan; Wong, Rosa S.; Li, Xue; Chen, Peng; Li, Shuai; Chui, Celine S.; Tso, Winnie WY.; Ho, Marco HK.; Wong, Ian CK.; Chan, Godfrey CF.; Lau, Yu Lung; Wong, Kenneth KY.; Chung, Patrick HY.; Li, Hui; Tam, Paul KH.; Tang, Shao-tao; Patrick lp title: A Comparison Between Chinese Children Infected with COVID-19 and with SARS date: 2020-06-18 journal: J Pediatr DOI: 10.1016/j.jpeds.2020.06.041 sha: eb01bbacca9953df869719548bdf2a72d795ec26 doc_id: 987443 cord_uid: phmvqhsm OBJECTIVES: To compare the clinical and laboratory features of severe acute respiratory syndrome 2003 (SARS) and coronavirus disease 2019 (COVID-19) in two Chinese pediatric cohorts, given that the causative pathogens and are biologically similar., STUDY DESIGN: This is a cross-sectional study reviewing paediatric patients with SARS (n = 43) and COVID-19 (n=244) who were admitted to the Princess Margaret Hospital in Hong Kong and Wuhan Children’s Hospital in Wuhan, respectively. Demographics, hospital length of stay, clinical and laboratory features were compared RESULTS: Overall, 97.7% of patients with SARS and 85.2% of patients with COVID-19 had epidemiological associations with known cases. Significantly more patients with SARS developed fever, chills, myalgia, malaise, coryza, sore throat, sputum production, nausea, headache, and dizziness than patients COVID-19. No SARS patients were asymptomatic at the time of admission. 29.1% and 20.9% COVID-19 patients were asymptomatic on admission and throughout their hospital stay, respectively. More SARS patients required oxygen supplementation than COVID-19 patients (18.6 vs. 4.7%, P = 004). Only 1.6% COVID-19 and 2.3% SARS patients required mechanical ventilation. Leukopenia (37.2% vs. 18.6%, p=0.008), lymphopenia (95.4% versus 32.6%, p<0.01), and thrombocytopenia (41.9% vs 3.8%, p<0.001) were significantly more common in SARS than COVID-19 patients. The duration between positive and negative nasopharyngeal aspirate and the length in hospital stay were similar in COVID-19 patients regardless of whether they were asymptomatic or symptomatic, suggesting a similar duration of viral shedding. CONCLUSIONS: Children with COVID-19 were less symptomatic and had more favorable hematological findings than children with SARS. The authors declare no conflicts of interest. To compare the clinical and laboratory features of severe acute respiratory syndrome 2003 (SARS) and coronavirus disease 2019 in two Chinese pediatric cohorts, given that the causative pathogens and are biologically similar., This is a cross-sectional study reviewing paediatric patients with SARS (n = 43) and who were admitted to the Princess Margaret Hospital in Hong Kong and Wuhan Children's Hospital in Wuhan, respectively. Demographics, hospital length of stay, clinical and laboratory features were compared Overall, 97.7% of patients with SARS and 85.2% of patients with COVID-19 had epidemiological associations with known cases. Significantly more patients with SARS developed fever, chills, myalgia, malaise, coryza, sore throat, sputum production, nausea, headache, and dizziness than patients COVID-19. No SARS patients were asymptomatic at the time of admission. 29.1% and 20.9% COVID-19 patients were asymptomatic on admission and throughout their hospital stay, respectively. More SARS patients required oxygen supplementation than COVID-19 patients (18.6 vs. 4 .7%, P = .004). Only 1.6% COVID-19 and 2.3% SARS patients required mechanical ventilation. Leukopenia (37.2% vs. 18.6%, p=0.008), lymphopenia (95.4% versus 32.6%, p<0.01), and thrombocytopenia (41.9% vs 3.8%, p<0.001) were significantly more common in SARS than COVID-19 patients. The duration between positive and negative nasopharyngeal aspirate and the length in hospital stay were similar in COVID-19 patients regardless of whether they were asymptomatic or symptomatic, suggesting a similar duration of viral shedding. Children with COVID-19 were less symptomatic and had more favorable hematological findings than children with SARS. Both SARS-CoV and SARS-CoV-2 belong to the betacoronavirus genus and are phylogenetically related to bat SARS-like coronavirus, but relatively more distantly to MERS-CoV. Both SARS-CoV and SARS-CoV-2 share 79% genetic similarity 3 . They also share similar infection pathophysiology in humans, as they both bind to the same human receptor, angiotensin-converting enzyme 2 (ACE2), for entry into host cells. However, SARS-CoV-2 has higher transmissibility, with a higher reproductive number (R 0 ) of 2-2.5 compared with 1.7-1.9 for SARS-CoV. 4 Studies from Wuhan describing the clinical characteristics of 171 COVID-19 children showed that 15.8% of patients in their cohort were asymptomatic carriers, and only one patient required intensive care with ventilator support. 5 In contrast, previous studies summarizing the clinical characteristics of pediatric SARS patients showed they were almost all symptomatic. 4 A serological study showed that asymptomatic SARS cases in children was rare. 6 Furthermore, compared with other coronavirus infections that cause milder diseases, both SARS and COVID-19 have significantly higher morbidity and mortality. 7 Nevertheless, studies providing a direct comparison of clinical and laboratory features between children infected with SARS and COVID-19 are lacking. In this study, we investigated the clinical and laboratory features in two representative Chinese pediatric cohorts with SARS and COVID-19. Understanding the differences and similarities in the clinical phenotypes and laboratory measures in pediatric patients with SARS and COVID-19 will guide us in the identification, quarantine, and management of infected children in a timely manner. This was a comparative study examining the clinical and laboratory features of Chinese children Duration between positive and negative NPA was defined as the time between the first SARS-CoV-2 positive NPA specimen and the first of two consecutive NPA negative specimens. Asymptomatic patients were defined in Wuhan as no clinical symptoms and no abnormal computed tomography (CT) findings, as all COVID-19 patients received CT scan of the thorax prior transferral or after admission to the Wuhan Children's Hospital. 9 Both COVID-19 and SARS patients were discharged after resolution of the clinical symptoms and after receiving two consecutive negative NPA tests for SARS-CoV-2 and SARS-CoV, respectively. SARS patients were also mandated to stay in the hospital for 21 days from symptoms onset. Continuous variables were expressed as mean ± standard deviation (SD) or median (interquartile range, IQR) and analysed by independent t-test or Mann-Whitney U test where appropriate. Categorical variables for SARS, symptomatic COVID-19, and asymptomatic COVID-19 groups were expressed as number (%) and analysed by Chi-square test, Fisher exact test, or ANOVA. Age-and sexmatched references from Chinese children were used for comparing blood measures. A two-sided α of <0.05 was considered statistically significant. Patients with missing data will not be analysed for A total of 43 SARS and 244 COVID-19 pediatric patients were recruited into the study. Demographic and clinical characteristics are shown in Table I . The median age of the COVID-19 cohort was 82 months and the SARS cohort was 160.8 months (Figure 1 ). There were a total of 85 (34.8%) asymptomatic COVID-19 patients compared with no asymptomatic SARS patients at presentation Overall, 97.7% (42/43) SARS and 85.2% (208/242) COVID-19 cases had identifiable epidemiologic links in known cases. In the COVID-19 cohort, a 10-month-old boy died of intussusception and multiorgan failure, which has been reported elsewhere. 5 No mortality was reported in the SARS cohort. There were no significant differences in the time from positive to negative NPA between symptomatic and asymptomatic COVID-19 groups (mean 8.2 days versus 8.9 days, p=0.434). There were also no significant differences in the LOS in hospital between symptomatic and asymptomatic COVID-19 patients (mean 13.0 days versus 11.4 days, p=0.066), but the LOS in the SARS cohort (all symptomatic) was significantly longer than in the symptomatic COVID-19 cohort (mean 20.6 days versus 12.9 days, p<0.001). Comparison of symptoms between the SARS and COVID-19 cohorts are presented in Table 1 and patients. Cough symptoms occurred similarly in both cohorts. More SARS patients required oxygen supplementation than COVID-19 patients (18.6% versus 4.7%, p=0.004), whereas only 1.6% and 2.3% of COVID-19 and SARS patients required mechanical ventilatory support, respectively. Laboratory testing results for SARS and symptomatic COVID-19 patients are presented in Table 2 . SARS patients had significantly lower total white blood cell count (p=0.043), lymphocyte count (p<0.001), and platelet (p<0.001) count, and lower albumin (p<0.001), higher globulin (p<0.001), higher ALT (p=0.01), and lower D-Dimer (p<0.001) levels. We further explored the number of children with leukopenia, lymphopenia and thrombocytopenia using age-and sex-matched reference ranges for Chinese and Asian children. 10 were significantly more common in SARS than in COVID-19 patients. The laboratory test results for the asymptomatic COVID-19 patients were normal. In our study of Chinese children infected with COVID-19 and SARS in representative paediatric cohorts from Wuhan and Hong Kong. COVID-19 patients experienced fewer symptoms than SARS patients. Almost all SARS patients presented with fever compared with only half of COVID-19 patients, which suggests screening by body temperature will potentially miss half of the children infected with COVID-19. Although a similar percentage of patients in both cohorts had a cough, significantly more SARS patients had other symptoms including fever and respiratory difficulties. 8 Only a few children in both cohorts required oxygen therapy and mechanical ventilation. In contrast to adult patients, our results echo that children infected by either SARS-CoV-2 or SARS-CoV had a good prognosis. 15 16 Indeed, studies have shown that a higher percentage of older adults with COVID-19 develop complications including pneumonia, acute myocardial injury, and acute respiratory distress syndrome, with an overall mortality of up to 11% in some populations. 17 Similar observations were reported during the SARS-CoV epidemic in 2003, which had 7% and 17% mortality in Mainland China and Hong Kong, respectively. 2 The majority of the patients who died from SARS and COVID-19 were older patients with underlying chronic illnesses or who were immunocompromised. 18 A study comparing published data in the literature also concurred with our findings that SARS and COVID-19 infected children had favorable outcomes. 19 One possible explanation why children are less affected by both SARS and COVID-19 is the different expressions of ACE2 in children and adults. The ACE2 receptor is crucial for both SARS-CoV and SARS-CoV-2 to enter into host cells. 20 It has been demonstrated that ACE2 expression can influence the infectivity of SARS-CoV in vitro. 21 Nevertheless, studies demonstrating age variation of ACE2 expression currently are lacking. Our study also showed there were significantly more asymptomatic carriers in the pediatric COVID-19 group, but none in the paediatric SARS group. This finding was consistent with studies in adults with SARS, which found only a few asymptomatic adults or healthcare workers who tested antibodypositive after the epidemic, 22 or had only mild and self-limiting symptoms. 23 To the contrary, asymptomatic COVID-19 infections were reported to be common among adults and younger adults without co-morbidities. 24 Asymptomatic transmission of SARS-CoV-2 may be one of the key factors leading to the pandemic. 25 In our study, the average time to achieve a negative NPA and hospital LOS were similar for symptomatic and asymptomatic COVID-19 patients, which indicates that clearance of COVID-19 virus may be similar for symptomatic and asymptomatic patients. A difficulty in concluding this is that dating of the first specimen at the onset in symptomatic patients cannot be replicated in asymptomatic patients. Although we found the LOS in hospital for the SARS cohort was significantly longer than that for the symptomatic COVID-19 cohort (20.6 days versus 11.4 days, p<0.001), a difference in the isolation policy between the two outbreaks likely confounded this observation. In the SARS outbreak in 2003, the mandatory hospitalization for patients was 21 days from symptoms onset in addition to a negative NPA and resolution of symptoms. More importantly, our study also revealed that 35.6% of children infected with SARS-CoV-2 were asymptomatic on We found that the COVID-19 cohort had more favorable hematologic and biochemical findings, with fewer COVID-19 patients having abnormal test results compared with SARS patients. The mean total white blood cell, lymphocyte, and median platelet counts in SARS patients were all significantly lower than in COVID-19 patients. Potential mechanisms include direct infection of haematopoietic progenitor cells via cell surface CD13 or CD66a that possibly induces growth inhibition and apoptosis. 27 Although the COVID-19 cohort was significantly younger than the SARS cohort, significantly fewer children in the COVID-19 cohort had hematological abnormalities when using ageand sex-matched references. Lymphopenia was observed during the early phase of the SARS epidemic, 28 predominantly CD4+ and CD8+ lymphopenia, 29 and adult SARS-CoV patients who were clinically more severe or died had significantly more severe CD4+ and CD8+ lymphopenia. In COVID-19 infection, the degree of lymphopenia was reported to be a prognostic indicator for older patients. 30 The significantly lower proportion of pediatric COVID-19 patients with lymphopenia may explain the milder phenotype compared with the SARS group. This study had several limitations. First, this was retrospective observational study design, which may have potential recall or sampling bias. Nevertheless, the majority of COVID-19 children under the age of 18 in Wuhan were admitted to the Wuhan Children's Hospital, whereas the majority SARS pediatric patients in Hong Kong were admitted to PMH. Wuhan and Hong Kong were among the most seriously affected cities in the COVID-19 and SARS outbreaks, respectively. Therefore, they are representative pediatric cohorts for these two infections. Second, not all family contacts of SARS cases were tested in 2003. Nevertheless, in the study conducted by Lee et al, only 0.57% of asymptomatic children from the Amoy Garden were positive for SARS-CoV antibody. None of the 14 asymptomatic children who had contacts with SARS patients were seropositive. 6 The Amoy Garden was one of the housing estates in Hong Kong with major community outbreak. It was also where the majority of the SARS-infected children in this cohort were recruited. Therefore, despite the lack of close contact screening in 2003, SARS asymptomatic carriage was considered to be rare. Third, younger COVID-19 patients may not be able to describe their subjective symptoms, such as anosmia that is considered a novel symptom of COVID-19, 31 which may lead to under-reporting of these symptoms. Fourth, CT and other radiologic findings were not reported in details as the majority of the SARS patients did not have CT performed and therefore was considered out of the scope of this manuscript. Radiologic findings of some of the patients from Wuhan's Children Hospital have been reported elsewhere. 9 Fifth, a recent phylogenetic network study showed that the predominant SARS-CoV-2 variant (type B) in East Asia is genetically different from the variants in Europe and America (type A and C). Whether such differences lead to different clinical characteristics between Asia and the West remains uncertain, and one must be cautious in extrapolating clinical characteristics of COVID-19 in Asia to other geographic areas. 32 Finally, we did not observe any children developing Kawasaki-like hyperinflammatory shock that was reported in European COVID-13 19 children in our Chinese cohort. 33 34 Future studies combining and comparing data from international clinical centers will be meaningful to examine the demographics and clinical spectrum of pediatric COVID-19 patients on a global perspective, and to further identify the risk factors for these severe diseases. COVID-19) Pandemic: World Health Organization World Health Organization Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding COVID-19, SARS and MERS: are they closely related? SARS-CoV-2 Infection in Children Risk-stratified seroprevalence of severe acute respiratory syndrome coronavirus among children in Hong Kong Coronavirus HKU1 and other coronavirus infections in Hong Kong Severe Acute Respiratory Syndrome Among Children A single-center, retrospective study of COVID-19 features in children: a descriptive investigation Reference values for peripheral blood lymphocyte subsets of healthy children in China Age-and sex-specific reference intervals for hematologic analytes in Chinese children Complete Blood Count Reference Intervals and Patterns of Changes Across Pediatric, Adult, and Geriatric Ages in Korea Severe acute respiratory syndrome in children Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19 Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults Severe acute respiratory syndrome in children: experience in a regional hospital in Hong Kong The many estimates of the COVID-19 case fatality rate. The Lancet Infectious Diseases Covid-19: risk factors for severe disease and death The curious case of coronavirus disease 2019 (COVID-19) in children COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia A Patient with Asymptomatic Severe Acute Respiratory Syndrome (SARS) and Antigenemia from the 2003-2004 Community Outbreak of SARS in Guangzhou, China Severe acute respiratory syndrome can be mild in children The clinical feature of silent infections of novel coronavirus infection (COVID-19) in Wenzhou Presumed Asymptomatic Carrier Transmission of COVID-19 COVID-19 epidemic: disentangling the re-emerging controversy about medical facemasks from an epidemiological perspective Hematological findings in SARS patients and possible mechanisms (review) Lymphopenia in SARS Expression of lymphocytes and lymphocyte subsets in patients with severe acute respiratory syndrome Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome? Phylogenetic network analysis of SARS-CoV-2 genomes Hyperinflammatory shock in children during COVID-19 pandemic COVID-19 and Kawasaki Disease: Novel Virus and Novel Case We thank all the staff members of the Department of Paediatrics and Adolescent Medicine, the Princess Margaret Hospital, and Wuhan Children's Hospital for their dedication in caring for sick children, which can be a very difficult time for both patients and their families.